What Should Be the First-Choice Strategy To Maximize Posaconazole Exposure in Daily Clinical Practice?
- 1 August 2009
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (8), 3608-3610
- https://doi.org/10.1128/aac.00256-09
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Omeprazole Significantly Reduces Posaconazole Serum Trough LevelClinical Infectious Diseases, 2009
- Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic SyndromePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
- Therapeutic Drug Monitoring of Antifungals: Pharmacokinetic and Pharmacodynamic ConsiderationsTherapeutic Drug Monitoring, 2008
- Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled TrialClinical Infectious Diseases, 2007
- Oral Bioavailability of Posaconazole in Fasted Healthy SubjectsClinical Pharmacokinetics, 2005
- Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adultsBritish Journal of Clinical Pharmacology, 2003